The U.S. Food and Drug Administration approved the drug Sunitinib (marketed as Sutent) to treat patients with kidney cancer who are at high risk for tumor recurrence. Dr. Allan Pantuck, head of the UCLA Institute of Urologic Oncology’s Clinical Research Program, served on the Global Advisory Steering Committee that oversaw the conduct and progress of a clinical study of sunitinib and helped to present these findings to the FDA’s Oncologic Drugs Advisory Committee.
Study Shows Multimodal Approach Improves Survival in Aggressive Prostate Cancer
The study, led by UCLA researcher Dr. Amar Kishan, shows that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.
Be Part of a Clinical Study.
Active Clinical Trials >
View answers to frequently asked questions
Why Choose the UCLA Institute of Urologic Oncology? >